Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 436

1.

Synthesis and biological evaluation of 3-(azolylmethyl)-1H-indoles and 3-(alpha-azolylbenzyl)-1H-indoles as selective aromatase inhibitors.

Le Borgne M, Marchand P, Nourrisson MR, Loquet D, Palzer M, Le Baut G, Hartmann RW.

J Enzyme Inhib Med Chem. 2007 Oct;22(5):667-76.

PMID:
18035835
2.

Preparation and pharmacological profile of 7-(alpha-azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors.

Marchand P, Le Borgne M, Palzer M, Le Baut G, Hartmann RW.

Bioorg Med Chem Lett. 2003 May 5;13(9):1553-5.

PMID:
12699753
3.

Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1H-indoles and 3-(1-azolyl-1-phenylmethyl)-1H-indoles as inhibitors of P450 arom.

Le Borgne M, Marchand P, Duflos M, Delevoye-Seiller B, Piessard-Robert S, Le Baut G, Hartmann RW, Palzer M.

Arch Pharm (Weinheim). 1997 May;330(5):141-5.

PMID:
9237426
4.

2- and 3-[(aryl)(azolyl)methyl]indoles as potential non-steroidal aromatase inhibitors.

Lézé MP, Le Borgne M, Marchand P, Loquet D, Kogler M, Le Baut G, Palusczak A, Hartmann RW.

J Enzyme Inhib Med Chem. 2004 Dec;19(6):549-57.

PMID:
15662958
5.

Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors.

Lézé MP, Le Borgne M, Pinson P, Palusczak A, Duflos M, Le Baut G, Hartmann RW.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1134-7. Epub 2005 Dec 27.

PMID:
16380254
6.

Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.

Lézé MP, Palusczak A, Hartmann RW, Le Borgne M.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4713-5. doi: 10.1016/j.bmcl.2008.06.094. Epub 2008 Jul 3.

PMID:
18640836
7.

New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles.

Le Borgne M, Marchand P, Delevoye-Seiller B, Robert JM, Le Baut G, Hartmann RW, Palzer M.

Bioorg Med Chem Lett. 1999 Feb 8;9(3):333-6.

PMID:
10091679
8.

A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.

Recanatini M, Bisi A, Cavalli A, Belluti F, Gobbi S, Rampa A, Valenti P, Palzer M, Palusczak A, Hartmann RW.

J Med Chem. 2001 Mar 1;44(5):672-80.

PMID:
11262078
9.

Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.

Stefanachi A, Favia AD, Nicolotti O, Leonetti F, Pisani L, Catto M, Zimmer C, Hartmann RW, Carotti A.

J Med Chem. 2011 Mar 24;54(6):1613-25. doi: 10.1021/jm101120u. Epub 2011 Feb 22.

PMID:
21341743
10.

Retinoic acid metabolism inhibition by 3-azolylmethyl-1H-indoles and 2, 3 or 5-(alpha-azolylbenzyl)-1H-indoles.

Le Borgne M, Marchand P, Le Baut G, Ahmadi M, Smith HJ, Nicholls PJ.

J Enzyme Inhib Med Chem. 2003 Apr;18(2):155-8.

PMID:
12943199
11.

Synthesis and antileishmanial activity of 3-(alpha-azolylbenzyl)indoles.

Marchand P, Le Borgne M, Na YM, Pagniez F, Abdala H, Le Baut G, Le Pape P.

J Enzyme Inhib Med Chem. 2002 Dec;17(6):353-8.

PMID:
12683669
12.

Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation.

Gobbi S, Zimmer C, Belluti F, Rampa A, Hartmann RW, Recanatini M, Bisi A.

J Med Chem. 2010 Jul 22;53(14):5347-51. doi: 10.1021/jm100319h.

PMID:
20568782
13.

Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors.

Leonetti F, Favia A, Rao A, Aliano R, Paluszcak A, Hartmann RW, Carotti A.

J Med Chem. 2004 Dec 30;47(27):6792-803.

PMID:
15615528
14.

Imidazolylmethylbenzophenones as highly potent aromatase inhibitors.

Gobbi S, Cavalli A, Negri M, Schewe KE, Belluti F, Piazzi L, Hartmann RW, Recanatini M, Bisi A.

J Med Chem. 2007 Jul 26;50(15):3420-2. Epub 2007 Jun 22.

PMID:
17585752
15.

Potent CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: synthesis and biological evaluation.

Saberi MR, Vinh TK, Yee SW, Griffiths BJ, Evans PJ, Simons C.

J Med Chem. 2006 Feb 9;49(3):1016-22.

PMID:
16451067
17.

Synthesis and biological evaluation of imidazole based compounds as cytochrome P-450 inhibitors.

Ahmed S, Smith JH, Nicholls PJ, Whomsley R, Cariuk P.

Drug Des Discov. 1995 Aug;13(1):27-41.

PMID:
8882899
18.

Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.

Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, Barassin C, Marchais-Oberwinkler S, Hartmann RW.

J Med Chem. 2005 Oct 20;48(21):6632-42.

PMID:
16220979
19.

Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.

Ulmschneider S, Müller-Vieira U, Mitrenga M, Hartmann RW, Oberwinkler-Marchais S, Klein CD, Bureik M, Bernhardt R, Antes I, Lengauer T.

J Med Chem. 2005 Mar 24;48(6):1796-805.

PMID:
15771425
20.

Synthesis and biological evaluation of novel pyrrolidine-2,5-dione inhibitors as potential anti-tumour agents.

Ahmed S, Smith JH, Nicholls PJ, Whomsley R, Cariuk P.

Drug Des Discov. 1995 Apr;12(4):275-87.

PMID:
9040988
Items per page

Supplemental Content

Write to the Help Desk